GeoVax Receives Notice of Allowance for Zika Vaccine Patent

ATLANTA, GA, Jan. 25, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 17/000,768 titled, “Method for Generating a ZIKV Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector Encoding the NS1 Protein.”

Read the full press release here.